On March 1st, 2023, Eli Lilly announced in a news release it plans to cap out-of-pocket insulin costs for patients using many of its insulins to $35. These dramatic price cuts aim to make a vital medication for people with diabetes needing it to manage their blood glucose and prolong their lives more affordable. As Eli Lilly Chair and CEO David Rick stated,
“While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone… the aggressive price cuts we’re announcing today should make a real difference for Americans with diabetes.”
Other major insulin
